Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Cassidy Suggests Importing Generics From EU To Pressure US Prices

Executive Summary

Idea may require tweaking existing agreements between FDA and EMA, but is another twist on drug importation, a concept that FDA opposes.

You may also be interested in...



Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely

Upcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.

Brand 'Evergreening' Piques FDA Interest, But Solutions Remain Elusive

Agency eager to hear suggestions on the subject, also known as product hopping, but even reform advocates were cautious of stifling meaningful reformulations of products.

Related Content

Topics

UsernamePublicRestriction

Register

PS121152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel